<DOC>
	<DOCNO>NCT01032980</DOCNO>
	<brief_summary>This study design assess safety approve licensed HUMENZA ( adjuvanted A/H1N1 pandemic influenza vaccine ) PANENZA ( non-adjuvanted A/H1N1 pandemic influenza vaccine ) meet regulatory requirement post-marketing safety monitoring . Primary objective : To describe incidence serious adverse event adverse event special interest ( AESIs ) HUMENZA PANENZA administration throughout study different age group . Secondary objective : To describe incidence non-serious cutaneous allergic reaction HUMENZA PANENZA administration different age group 21 day last vaccination.This study design assess safety approve licensed HUMENZA ( adjuvanted A/H1N1 pandemic influenza vaccine ) PANENZA ( non-adjuvanted A/H1N1 pandemic influenza vaccine ) meet regulatory requirement post-marketing safety monitoring .</brief_summary>
	<brief_title>Post Authorization Safety Study Pandemic A/H1N1 Influenza Vaccines Children Adults</brief_title>
	<detailed_description>All participant vaccinate study vaccine ( 1 2 dos ) start study monitor safety 6 month last vaccination .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria : Aged 2 month day inclusion Having receive HUMENZA PANENZA Provision Contact Order Form ( COF ) sign participant participant 's parent ( ) /guardians ( ) Participant participant 's parent ( ) /legal representative ( ) able attend schedule visit comply study procedure Exclusion Criteria : Participant previously vaccinate another A/H1N1 pandemic vaccine</criteria>
	<gender>All</gender>
	<minimum_age>2 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>HUMENZA</keyword>
	<keyword>PANENZA</keyword>
	<keyword>Influenza</keyword>
	<keyword>Swine-Origin Influenza A H1N1 Virus</keyword>
	<keyword>Influenza virus vaccine</keyword>
</DOC>